Dr. Robert T. Naismith, MD
Neurology (Neurology Physician)
4921 Parkview Pl, Div Neurology Multiple Sclerosis, 7th Fl
Saint Louis, MO 63110
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 79
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MO license 2000146127
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Missouri Baptist Medical Center Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Memorial Hospital Belleville, IL
- Parkland Health Center Farmington, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 79
- Services billed
- 143
- Patients’ average age
- 64
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 39 | 33 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 21 | 20 |
| Established patient office or other outpatient visit, 10-19 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Saint Louis, MO | 124 |
| Baclofen Other prescribers in Saint Louis, MO | 91 |
| Kesimpta Pen (ofatumumab) | 54 |
| Teriflunomide | 52 |
| Amitriptyline Hcl Other prescribers in Saint Louis, MO | 48 |
| Trazodone Hcl Other prescribers in Saint Louis, MO | 43 |
| Fingolimod (fingolimod hcl) | 39 |
| Pregabalin Other prescribers in Saint Louis, MO | 32 |
| Dalfampridine Er (dalfampridine) | 31 |
| Myrbetriq (mirabegron) Other prescribers in Saint Louis, MO | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 67 payments worth $145,927 in total to this clinician.
| Sanofi-aventis U.S. LLC | $72,450 |
|---|---|
| Genzyme Corporation | $38,061 |
| E.r. Squibb & Sons, L.l.c. | $10,503 |
| Amgen Inc. | $8,123 |
| Tg Therapeutics, Inc. | $5,154 |
| Novartis Pharma AG | $3,300 |
| Genentech, Inc. | $2,760 |
| AstraZeneca Pharmaceuticals LP | $2,331 |
| Consulting Fee | $92,994 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $45,161 |
| Travel and Lodging | $6,224 |
| Food and Beverage | $1,549 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $11,074 |
| Genzyme Corporation Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $11,074 |
| Genzyme Corporation Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,808 |
| Sanofi-aventis U.S. LLC Oct 15, 2025 | Consulting Fee | $10,500 |
| Sanofi-aventis U.S. LLC Nov 15, 2025 | Consulting Fee | $10,500 |
| Sanofi-aventis U.S. LLC Mar 12, 2025 | Consulting Fee | $9,600 |
| Sanofi-aventis U.S. LLC Sep 15, 2025 | Consulting Fee | $8,850 |
| Sanofi-aventis U.S. LLC Jul 15, 2025 | Consulting Fee | $7,050 |
| Sanofi-aventis U.S. LLC Dec 15, 2025 | Consulting Fee | $6,600 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Consulting Fee | $5,038 |
All 50 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Sanofi-aventis U.S. LLC Dec 15, 2025 | Consulting Fee | $6,600 |
| Sanofi-aventis U.S. LLC Dec 15, 2025 | Consulting Fee | $1,350 |
| Genzyme Corporation Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $11,074 |
| Genzyme Corporation Dec 11, 2025 | Travel and Lodging travel to Aurora, CO | $669 |
| Genzyme Corporation Dec 11, 2025 | Travel and Lodging travel to Aurora, CO | $176 |
| AstraZeneca Pharmaceuticals LP Dec 5, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,331 |
| Amgen Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,300 |
| Sanofi-aventis U.S. LLC Nov 15, 2025 | Consulting Fee | $10,500 |
| Sanofi-aventis U.S. LLC Nov 15, 2025 | Consulting Fee | $1,350 |
| Genzyme Corporation Nov 15, 2025 | Consulting Fee | $137 |
| Genzyme Corporation Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $11,074 |
| Genzyme Corporation Oct 29, 2025 | Travel and Lodging travel to Milwaukee, WI | $661 |
| Genzyme Corporation Oct 29, 2025 | Travel and Lodging travel to Milwaukee, WI | $202 |
| Sanofi-aventis U.S. LLC Oct 15, 2025 | Consulting Fee | $10,500 |
| Sanofi-aventis U.S. LLC Oct 15, 2025 | Consulting Fee | $1,350 |
| Genzyme Corporation Oct 15, 2025 | Consulting Fee | $546 |
| H. Lundbeck A S Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $870 |
| Sanofi-aventis U.S. LLC Sep 15, 2025 | Consulting Fee | $8,850 |
| Sanofi-aventis U.S. LLC Sep 15, 2025 | Consulting Fee | $1,350 |
| Genzyme Corporation Sep 15, 2025 | Consulting Fee | $410 |
| E.r. Squibb & Sons, L.l.c. Sep 9, 2025 | Consulting Fee | $1,268 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Consulting Fee | $5,038 |
| Amgen Inc. Aug 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,300 |
| Amgen Inc. Aug 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $550 |
| Amgen Inc. Aug 22, 2025 | Travel and Lodging travel to Paducah, KY · in-kind | $713 |
| Sanofi-aventis U.S. LLC Aug 15, 2025 | Consulting Fee | $4,950 |
| Sanofi-aventis U.S. LLC Aug 15, 2025 | Consulting Fee | $1,050 |
| Celltrion, Inc. Aug 11, 2025 | Consulting Fee | $570 |
| Vertex Pharmaceuticals Incorporated Jul 21, 2025 | Consulting Fee | $500 |
| Sanofi-aventis U.S. LLC Jul 15, 2025 | Consulting Fee | $7,050 |
| Sanofi-aventis U.S. LLC Jul 15, 2025 | Consulting Fee | $450 |
| Novartis Pharma AG Jun 2, 2025 | Consulting Fee Rhapsido · Others | $3,300 |
| E.r. Squibb & Sons, L.l.c. May 30, 2025 | Travel and Lodging travel to New Orleans, LA · in-kind | $513 |
| Tg Therapeutics, Inc. Apr 26, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $4,185 |
| Tg Therapeutics, Inc. Apr 26, 2025 | Travel and Lodging BRIUMVI · Immunology · travel to Dallas, TX | $164 |
| Tg Therapeutics, Inc. Apr 25, 2025 | Travel and Lodging BRIUMVI · Immunology · travel to Dallas, TX · in-kind | $285 |
| Genzyme Corporation Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,808 |
| Genzyme Corporation Apr 23, 2025 | Travel and Lodging travel to Fort Collins, CO · in-kind | $827 |
| Genzyme Corporation Apr 23, 2025 | Travel and Lodging travel to Fort Collins, CO · in-kind | $598 |
| Genzyme Corporation Apr 23, 2025 | Travel and Lodging travel to Fort Collins, CO | $384 |
| Genzyme Corporation Apr 23, 2025 | Travel and Lodging travel to Fort Collins, CO | $97.78 |
| E.r. Squibb & Sons, L.l.c. Apr 8, 2025 | Consulting Fee | $3,686 |
| Sanofi-aventis U.S. LLC Mar 12, 2025 | Consulting Fee | $9,600 |
| Sanofi-aventis U.S. LLC Mar 12, 2025 | Consulting Fee | $150 |
| Novartis Pharmaceuticals Corporation Feb 19, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $572 |
| Novartis Pharmaceuticals Corporation Feb 19, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $280 |
| Novartis Pharmaceuticals Corporation Feb 19, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $82.00 |
| Sanofi-aventis U.S. LLC Feb 12, 2025 | Consulting Fee | $4,950 |
| Genentech, Inc. Jan 9, 2025 | Consulting Fee | $2,760 |
| Sanofi-aventis U.S. LLC Jan 8, 2025 | Consulting Fee | $2,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 19 industry-funded studies in 2025, from 6 companies. The companies reported $2,304,911 in research payments for these studies, mostly to the institutions running them.
- A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neuro…
E.r. Squibb & Sons, L.l.c. - Satralizumab in MOG AD
Genentech, Inc. - Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE
F. Hoffmann-la Roche AG - A phase iii study to evaluate the efficacy and safety of fenebrutinib in adults with progressive ms
Genentech, Inc. - A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neuro…
Celgene Corporation - Ocrelizumab RMS High Dose Study
Genentech, Inc. - An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
Novartis Pharmaceuticals Corporation - Ocrelizumab PPMS High Dose Study
Genentech, Inc. - A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc. - OCARINA I
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.